The DOI matches its Crossref record; 323 of the 328 references it cites were found in a registry or an index.
Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach
Abstract
Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in liver and muscle and impaired insulin secretion. Considerable evidence also implicates deranged adipocyte metabolism and altered fat topography in the pathogenesis of glucose intolerance in T2DM. 1) Fat cells are resistant to insulin’s antilipolytic effect, leading to day-long elevated plasma FFA levels. Chronically increased plasma FFA stimulates gluconeogenesis, induces hepatic/muscle insulin resistance, and impairs insulin secretion in genetically predisposed individuals. These FFA-induced disturbances are referred to as lipotoxicity. 2) Dysfunctional fat cells produce excessive amounts of insulin resistance-inducing, inflammatory, and atherosclerotic-provoking cytokines and fail to secrete normal amounts of insulin-sensitizing adipocytokines. 3) Enlarged fat cells are insulin resistant and have diminished capacity to store fat. When adipocyte storage capacity is exceeded, lipid “overflows” into muscle, liver, and perhaps β-cells, causing muscle/hepatic insulin resistance and impaired insulin secretion. Thiazolidinediones enhance adipocyte insulin sensitivity, inhibit lipolysis, reduce plasma FFA, and favorably influence the production of adipocytokines. Thiazolidinediones also redistribute fat within the body (decreased visceral and hepatic fat; increased sc fat) and decrease intracellular concentrations of triglyceride metabolites in muscle, liver, and β-cells, contributing to improvements in muscle/hepatic insulin sensitivity and pancreatic function in type 2 diabetics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“an increased intramyocellar fat content and fatty acid metabolites have been shown to play a pivotal role in the development of insulin resistance in skeletal muscle [11–15].”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [14]
In the citing paper
“Dysregulation of fatty acid metabolism plays a pivotal role in the pathogenesis of insulin resistance in skeletal muscle.”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [14]
In the citing paper
“Considerable data implicate a causative role for elevated plasma FFA level in insulin resistance in skeletal muscle.”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [14]
In the citing paper
“It is well established that chronically elevated plasma FFA levels cause insulin resistance in skeletal muscle [1, 12, 14, 62–65].”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [14]
In the citing paper
“The important role of elevated plasma FFA in the pathogenesis of insulin resistance is now well established [12, 14, 57].”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [14]
In the citing paper
“Insulin resistance, in combination with b cell dysfunction, contributes to the development of type 2 diabetes (T2D) 4 (1).”
From A Lower-Carbohydrate, Higher-Fat Diet Reduces Abdominal and Intermuscular Fat and Increases Insulin Sensitivity in Adults at Risk of Type 2 Diabetes (2015) · cites this paper as [1]
In the citing paper
“Obesity, particularly visceral and ectopic adiposity, increases the risk of type 2 diabetes.”
From A Lower-Carbohydrate, Higher-Fat Diet Reduces Abdominal and Intermuscular Fat and Increases Insulin Sensitivity in Adults at Risk of Type 2 Diabetes (2015) · cites this paper as [1]
Citations
Cites
1 retracted
Insulin Binding to Monocytes and Insulin Action in Human Obesity, Starvation, and Refeeding
Defronzo, R. A., Soman, V., Sherwin, R. S., Hendler, R., & Felig, P. (1978) · Journal of Clinical Investigation · doi:10.1172/jci109108 · Cited by 252
Self-citationRetractedPositional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance
Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518
Randle, P. J., Garland, P. B., Hales, C. N., & Newsholme, E. A. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91500-9 · Cited by 5,093
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
The hormone resistin links obesity to diabetes
Steppan, C. M., Bailey, S. T., Bhat, S., Brown, E. J., Banerjee, R. R., Wright, C. M., Patel, H. R., Ahima, R. S., & Lazar, M. A. (2001) · Nature · doi:10.1038/35053000 · Cited by 4,755
DeFronzo, R. A., & Ferrannini, E. (1991) · Diabetes Care · doi:10.2337/diacare.14.3.173 · Cited by 4,555
Self-citationWeight-Reducing Effects of the Plasma Protein Encoded by the obese Gene
Halaas, J. L., Gajiwala, K. S., Maffei, M., Cohen, S. L., Chait, B. T., Rabinowitz, D., Lallone, R. L., Burley, S. K., & Friedman, J. M. (1995) · Science · doi:10.1126/science.7624777 · Cited by 4,451
Research works printed but not linked: 16
- Kelley, 1995, Effects of weight loss on glucose homeostasis in NIDDM., Diabetes Rev, 3, 366
- Schneider, 1995, Effects of fitness and physical training on carbohydrate metabolism and associated cardiovascular risk factors in patients with diabetes., Diabetes Rev, 3, 378
- Kashyap, 2002, Chronic elevation in plasma free fatty acids impairs insulin secretion in non-diabetic offspring with a strong family history of T2DM, Diabetes, 51, A12
- Miyazaki, 2002, Effect of pioglitazone on liver fat content, abdominal fat distribution, and insulin sensitivity in patients with type 2 diabetes mellitus, Diabetes, 51, A69
- Kashyap, 2002, A chronic physiologic increase in FFA in healthy subjects causes insulin signaling defects similar to those of insulin-resistant non-diabetic subjects with a strong family history of T2DM, Diabetes, 51, A24
- Seppala-Lindroos, 2002, Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men., J Clin Endocrinol Metab, 87, 3023, 10.1210/jcem.87.7.8638 · DOI · Paper page
- McTernan, 2002, Depot-specific expression of resistin in human adipose tissue and regulation of resistin secretion by insulin and rosiglitazone in human subcutaneous adipocytes in vitro, Diabetologia, 45, A66
- Groop, 1992, Effect of insulin on oxidative and non-oxidative pathways of glucose and free fatty acid metabolism in human obesity, Am J Physiol, 263, E79
- Krssak, 1999, Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study., Diabetologia, 42, 113, 10.1007/s001250051123 · DOI · Paper page
- Stein, 1999, Increasing intramyocellular triglyceride stores are associated with impaired glucose tolerance and NIDDM, Diabetes, 48, A287
- Greco, 2002, Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion., Diabetes, 51, 144, 10.2337/diabetes.51.1.144 · DOI · Paper page
- Kahsyap, 2003, Effect of sustained reduction in plasma FFA concentration on insulin secretion in non-diabetic subjects with a strong family history of T2DM, Diabetes, 52, A336
- Chilcott, 2001, A systematic review of the effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus., Clin Ther, 23, 1792, 10.1016/S0149-2918(00)80078-8 · DOI
- Finegood, 2001, β-Cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death., Diabetes, 50, 1021, 10.2337/diabetes.50.5.1021 · DOI
- Lupi, 2002, PPARγ ligand-specificity in the modulation of insulin release from isolated human islets in response to fatty acid incubation, Diabetologia, 45, A161
- Marselli, 2002, Rosiglitazone partially prevents free fatty acid-induced cytotoxicity of human pancreatic islet cells, Diabetologia, 45, A161
Cited by
Sorted by citations
Items 101–200 of 661
Konishi, M., Sugiyama, S., Sugamura, K., Nozaki, T., Ohba, K., Matsubara, J., Matsuzawa, Y., Sumida, H., Nagayoshi, Y., Nakaura, T., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.10.008 · Cited by 119
Diabesity: therapeutic options
Colagiuri, S. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01182.x · Cited by 121
Grahn, T. H. M., Kaur, R., Yin, J., Schweiger, M., Sharma, V. M., Lee, M., Ido, Y., Smas, C. M., Zechner, R., Lass, A., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.539890 · Cited by 117
Lipids and Lipid Mediators Associated with the Risk and Pathology of Ischemic Stroke
Kłoska, A., Malinowska, M., Gabig‐Cimińska, M., & Jakóbkiewicz‐Banecka, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103618 · Cited by 116
An Unsuspected Metabolic Role for Atrial Natriuretic Peptides
Lafontan, M., Moro, C., Sengenès, C., Galitzky, J., Crampes, F., & Berlan, M. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000183728.14712.d8 · Cited by 114
Madhavi, Y. V., Gaikwad, N. B., Yerra, V. G., Kalvala, A. K., Nanduri, S., & Kumar, A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180406120051 · Cited by 117
Is adiposopathy (sick fat) an endocrine disease?
Bays, H. E., González-Campoy, J. M., Henry, R. R., Bergman, D. A., Kitabchi, A. E., Schorr, A. B., Rodbard, H. W., & The Adiposopathy Working Group (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01848.x · Cited by 116
Self-citationFree fatty acids as a cardiovascular risk factor
Pilz, S., & März, W. (2008) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.118 · Cited by 114
Rosiglitazone decreases albuminuria in type 2 diabetic patients
Miyazaki, Y., Cersósimo, E., Triplitt, C. L., & DeFronzo, R. A. (2007) · Kidney International · doi:10.1038/sj.ki.5002516 · Cited by 112
Self-citationObesity and type 2 diabetes: which patients are at risk?
Garber, A. J. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01536.x · Cited by 114
Han, K. L., Jung, M. H., Sohn, J. H., & Hwang, J. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.110 · Cited by 111
Adipose tissue changes in obesity and the impact on metabolic function
Sam, S., & Mazzone, T. (2014) · Translational research · doi:10.1016/j.trsl.2014.05.008 · Cited by 113
Cellulite: nature and aetiopathogenesis
Terranova, F., Berardesca, E., & Maïbach, H. I. (2006) · International Journal of Cosmetic Science · doi:10.1111/j.1467-2494.2006.00316.x · Cited by 111
Pericardial fat inflammation correlates with coronary artery disease
Konishi, M., Sugiyama, S., Sato, Y. Z., Oshima, S., Sugamura, K., Nozaki, T., Ohba, K., Matsubara, J., Sumida, H., Nagayoshi, Y., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.007 · Cited by 108
Prevention of Diabetes With Pioglitazone in ACT NOW
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., et al. (2013) · Diabetes · doi:10.2337/db13-0265 · Cited by 109
Self-citationEctopic fat and insulin resistance
Lettner, A., & Roden, M. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0032-z · Cited by 106
Adiposopathy: Sick Fat Causes High Blood Sugar, High Blood Pressure and Dyslipidemia
Bays, H. E., Abate, N. I., & Chandalia, M. (2005) · Future Cardiology · doi:10.1517/14796678.1.1.39 · Cited by 108
Self-citationInsulin Resistance and Improvements in Signal Transduction
Musi, N., & Goodyear, L. J. (2006) · Endocrine · doi:10.1385/endo:29:1:73 · Cited by 104
Saraswathi, V., Gao, L., Morrow, J. D., Chait, A., Niswender, K. D., & Hasty, A. H. (2007) · Journal of Nutrition · doi:10.1093/jn/137.7.1776 · Cited by 103
Bays, H. E., Blonde, L., & Rosenson, R. S. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.6.871 · Cited by 103
Self-citationCounterpoint: Visceral Adiposity Is Not Causally Related to Insulin Resistance
Miles, J. M., & Jensen, M. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.9.2326 · Cited by 105
Koopmans, S. J., & Schuurman, T. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.044 · Cited by 103
Tharaheswari, M., Reddy, N. J., Kumar, R., Varshney, K. C., Kannan, M., & Sadras, S. R. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2152-x · Cited by 101
Phloretin enhances adipocyte differentiation and adiponectin expression in 3T3-L1 cells
Hassan, M., Yazidi, C. E., Landrier, J., Lairon, D., Margotat, A., & Amiot, M. J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.07.021 · Cited by 101
Adiposopathy, “Sick Fat,” Ockham’s Razor, and Resolution of the Obesity Paradox
Bays, H. E. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0409-1 · Cited by 103
Self-citationBrindley, D. N., Kok, B. P., Kienesberger, P. C., Lehner, R. S., & Dyck, J. R. B. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00509.2009 · Cited by 102
Sohaei, S., Amani, R., Tarrahi, M. J., & Ghasemi-Tehrani, H. (2019) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2019.102201 · Cited by 100
Gower, B. A., & Goss, A. M. (2015) · The Journal of Nutrition · doi:10.3945/jn.114.195065 · Cited by 98
Visceral white fat remodelling contributes to intermittent hypoxia-induced atherogenesis
Poulain, L., Thomas, A., Rieusset, J., Casteilla, L., Levy, P. A., Arnaud, C., & Demattéis, M. (2013) · European Respiratory Journal · doi:10.1183/09031936.00019913 · Cited by 102
Plasma Adiponectin Levels and Sonographic Phenotypes of Subclinical Carotid Artery Atherosclerosis
Iglseder, B., Mackēvičs, V., Stadlmayer, A., Tasch, G., Ladurner, G., & Paulweber, B. (2005) · Stroke · doi:10.1161/01.str.0000190834.00284.fd · Cited by 97
Jeninga, E. H., Bugge, A. K., Nielsen, R., Kersten, S., Hamers, N., Dani, C., Wabitsch, M., Berger, R., Stunnenberg, H. G., Mandrup, S., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040741 · Cited by 101
Pasarica, M., Rood, J. C., Ravussin, É., Schwarz, J., Smith, S. R., & Redman, L. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2377 · Cited by 96
Dyslipidemia in diabetic nephropathy
Kawanami, D., Matoba, K., & Utsunomiya, K. (2016) · Renal Replacement Therapy · doi:10.1186/s41100-016-0028-0 · Cited by 99
The role of obesity in the pathogenesis of hypertension
Bogaert, Y. E., & Linas, S. L. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph1022 · Cited by 95
López‐Tinoco, C., Roca, M., Fernández‐Deudero, Á., García-Valero, A., Bugatto, F., Aguilar‐Diosdado, M., & Bartha, J. L. (2011) · Cytokine · doi:10.1016/j.cyto.2011.12.004 · Cited by 97
Incretin Effects on β-Cell Function, Replication, and Mass
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s230 · Cited by 92
A1 Adenosine Receptor: Role in Diabetes and Obesity
Dhalla, A. K., Chisholm, J. W., Reaven, G. M., & Belardinelli, L. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_9 · Cited by 92
Mackawy, A. M. H., & Badawy, M. E.-S. (2014) · Meta Gene · doi:10.1016/j.mgene.2014.07.002 · Cited by 93
Pendergrass, M., Bertoldo, A., Bonadonna, R., Nucci, G., Mandarino, L., Cobelli, C., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00617.2005 · Cited by 87
Self-citationDiet‐induced obesity in Sprague–Dawley rats causes microvascular and neural dysfunction
Davidson, E. P., Coppey, L. J., Calcutt, N. A., Oltman, C. L., & Yorek, M. A. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1088 · Cited by 91
Liu, H., Chen, Y., Li, F., & Zhang, H. (2012) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2012.723203 · Cited by 90
Miyazaki, Y., & DeFronzo, R. A. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-44 · Cited by 93
Self-citationOh, D. Y., & Lagakos, W. (2011) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3283479230 · Cited by 91
An imbalance in serum concentrations of inflammatory and anti-inflammatory cytokines in hypertension
Mirhafez, S. R., Mohebati, M., Disfani, M. F., Karimian, M. S., Ebrahimi, M., Avan, A., Eslami, S., Pasdar, A., Rooki, H., Esmaily, H., et al. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.05.007 · Cited by 89
Park, K.-O., Ito, Y., NAGASAWA, T., Choi, M.-R., & NISHIZAWA, N. (2008) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.80395 · Cited by 93
Schinner, S., Willenberg, H. S., Krause, D., Schott, M., Lamounier‐Zepter, V., Krug, A. W., Ehrhart‐Bornstein, M., Bornstein, S. R., & Scherbaum, W. A. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803508 · Cited by 89
Yu, X., Ye, L., Zhang, H., Zhao, J., Wang, G., Guo, C., & Shang, W. (2014) · Journal of Ginseng Research · doi:10.1016/j.jgr.2014.11.004 · Cited by 88
Murdolo, G., & Smith, U. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.016 · Cited by 87
Treatment approach to type 2 diabetes: Past, present and future
Blaslov, K., Naranđa, F. S., Kruljac, I., & Renar, I. P. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i12.209 · Cited by 99
Lee, J., Kim, S. R., Yoo, S. J., Hong, O. K., Hs, S., & Chang, S. (2009) · Journal of International Medical Research · doi:10.1177/147323000903700616 · Cited by 88
Basal Insulin: Physiology, Pharmacology, and Clinical Implications
Niswender, K. D. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2300 · Cited by 91
The Effect of Pioglitazone on the Liver
Gastaldelli, A., Miyazaki, Y., Mahankali, A., Berria, R., Pettiti, M., Buzzigoli, E., Ferrannini, E., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2445 · Cited by 86
Self-citationEffects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
Bajaj, M. S., Baig, R., Suraamornkul, S., Hardies, L. J., Coletta, D. K., Cline, G. W., Monroy, A., Koul, S., Sriwijitkamol, A., Musi, N., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0911 · Cited by 86
Self-citationTiming of physical activity in relation to liver fat content and insulin resistance
van der Velde, J. H. P. M., Boone, S. C., Eekelen, E. W.-V., Hesselink, M. K. C., Schrauwen‐Hinderling, V. B., Schrauwen, P., Lamb, H. J., Rosendaal, F. R., & de Mutsert, R. (2022) · Diabetologia · doi:10.1007/s00125-022-05813-3 · Cited by 85
Gregoire, F. M., Zhang, F., Clarke, H. J., Gustafson, T. A., Sears, D. D., Favelyukis, S., Lenhard, J. M., Rentzeperis, D., Clemens, L. E., Mu, Y., et al. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0473 · Cited by 85
Diabetes mellitus: new challenges and innovative therapies
Sena, C. M., Bento, C. F., Pereira, P., & Seiça, R. M. F. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0010-9 · Cited by 92
Tripathy, D., Daniele, G., Fiorentino, T. V., Perez-Cadena, Z., Chavez-Velasquez, A., Kamath, S., Fanti, P., Jenkinson, C. P., Andreozzi, F., Federici, M., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2976-z · Cited by 83
Self-citationMurumalla, R. K., Gunasekaran, M., Padhan, J. K., Bencharif, K., Gence, L., Festy, F., Césari, M., Roche, R., & Hoareau, L. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-175 · Cited by 83
Kanat, M., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i12.1207 · Cited by 87
Self-citationManaging Type 2 Diabetes: Going Beyond Glycemic Control
STOLAR, M. W., Hoogwerf, B. J., Boyle, P. J., Gorshow, S. M., & Wales, D. O. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s5-b.1 · Cited by 82
Kawamoto, R., Ninomiya, D., Kasai, Y., Kusunoki, T., Ohtsuka, N., Kumagi, T., & Abe, M. (2016) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2015.1081232 · Cited by 81
Insulin Resistance and Metabolic Syndrome in the Pediatric Population
Nelson, R. A., & Bremer, A. A. (2009) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2009.0068 · Cited by 81
Harrity, T. W., Farrelly, D., Tieman, A., Chu, C., Kunselman, L., Gu, L., Ponticiello, R. P., Cap, M., Qu, F., Shao, C., et al. (2006) · Diabetes · doi:10.2337/diabetes.55.01.06.db05-0648 · Cited by 82
Shai, I., Schulze, M. B., Manson, J. E., Rexrode, K. M., Stampfer, M. J., Mantzoros, C. S., & Hu, F. B. (2005) · Diabetes Care · doi:10.2337/diacare.28.6.1376 · Cited by 81
Liu, Z., & Cao, W. (2009) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153009787582397 · Cited by 80
van Harmelen, V., Rydén, M., Sjölin, E., & Hoffstedt, J. (2006) · Journal of Lipid Research · doi:10.1194/jlr.m600272-jlr200 · Cited by 77
Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 79
Self-citationThiazolidinediones for the treatment of type 2 diabetes
Elte, J. W. F., & Blickle, J. (2007) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2006.09.007 · Cited by 77
RetractedPriscilla, D. H., Jayakumar, M., & Thirumurugan, K. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.02.005 · Cited by 75
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
The Effect of Rosiglitazone on the Liver: Decreased Gluconeogenesis in Patients with Type 2 Diabetes
Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., DeFronzo, R. A., & Ferrannini, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1159 · Cited by 75
Self-citationManaging insulin resistance: the forgotten pathophysiological component of type 2 diabetes
Abdul-Ghani, M. A., Maffei, P., & DeFronzo, R. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00127-x · Cited by 81
Self-citationAdiposopathy: why do adiposity and obesity cause metabolic disease?
Bays, H. E., & Ballantyne, C. M. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.389 · Cited by 75
Self-citationvan Can, J. G. P., van Loon, L. J. C., Brouns, F. J. P. H., & Blaak, E. E. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511006714 · Cited by 74
Liu, C., Feng, T., Zhu, N., Liu, P., Han, X., Chen, M., Xiao, W., Li, N., Li, Y., Xu, Y., et al. (2015) · Scientific Reports · doi:10.1038/srep09530 · Cited by 74
Bays, H. E. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.029 · Cited by 73
Self-citationGurnell, M. (2005) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.10.001 · Cited by 73
CEACAM1 modulates epidermal growth factor receptor–mediated cell proliferation
Abou-Rjaily, G. A., Lee, S. J., May, D., Al–Share, Q. Y., DeAngelis, A. M., Ruch, R. J., Neumaier, M., Kalthoff, H., Lin, S.-H., & Najjar, S. M. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421786 · Cited by 72
Mitochondrial fitness and insulin sensitivity in humans
Szendroedi, J., & Roden, M. (2008) · Diabetologia · doi:10.1007/s00125-008-1153-2 · Cited by 71
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Self-citationLiu, X., Cui, J., Li, Z., Xu, J., Wang, J., Xue, C., & Wang, Y. (2013) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.201300407 · Cited by 70
Insulin Resistance, Obesity, and Lipotoxicity
Yazıcı, D., Demir, S. Ç., & Sezer, H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_14 · Cited by 85
Ectopic fat: the true culprit linking obesity and cardiovascular disease?
Morelli, M., Gaggini, M., Daniele, G., Marraccini, P., Sicari, R., & Gastaldelli, A. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-04-0285 · Cited by 69
Monomeric cocoa catechins enhance β-cell function by increasing mitochondrial respiration
Rowley, T. J., Bitner, B. F., Ray, J. D., Lathen, D. R., Smithson, A. T., Dallon, B. W., Plowman, C. J., Bikman, B. T., Hansen, J. M., Dorenkott, M. R., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.07.015 · Cited by 69
Wallet, S. M., Puri, V., & Gibson, F. C. (2018) · Vaccines · doi:10.3390/vaccines6020021 · Cited by 69
Alipourfard, I., Datukishvili, N., & Mikeladze, D. (2019) · Mediators of Inflammation · doi:10.1155/2019/3560819 · Cited by 70
Bays, H. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.125 · Cited by 66
Self-citationInitial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
Zinman, B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.003 · Cited by 66
Weight changes following the initiation of new anti‐hyperglycaemic therapies
Nichols, G. A., & Gomez‐Caminero, A. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00580.x · Cited by 66
Nemes, A., Homoki, J. R., Kiss, R., Hegedűs, C., Kovács, D. K., Peitl, B., Gal, F., Stündl, L., Szilvássy, Z., & Remenyik, J. (2019) · Nutrients · doi:10.3390/nu11091966 · Cited by 72
Insulin Resistance, Dyslipidemia, and Cardiovascular Disease
Bloomgarden, Z. T. (2007) · Diabetes Care · doi:10.2337/dc07-zb08 · Cited by 67
Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Kitabchi, A. E., Mudaliar, S. R. D., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0520 · Cited by 65
Self-citationAttenuation of Vascular/Neural Dysfunction in Zucker Rats Treated With Enalapril or Rosuvastatin
Oltman, C. L., Davidson, E. P., Coppey, L. J., Kleinschmidt, T. L., Lund, D. D., & Yorek, M. A. (2008) · Obesity · doi:10.1038/oby.2007.19 · Cited by 63
Insulin resistance, diabetes and cardiovascular risk: approaches to treatment
Rosenberg, D. E., Jabbour, S. A., & Goldstein, B. J. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00446.x · Cited by 65
Abdul‐Ghani, M. A., Molina‐Carrión, M., Jani, R., Jenkinson, C. P., & DeFronzo, R. A. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0033-z · Cited by 63
Self-citationBays, H. E., Bindlish, S., & Clayton, T. L. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100056 · Cited by 68
Self-citationZhang, X., Shen, Y., Prinyawiwatkul, W., King, J. M., & Xu, Z. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.03.034 · Cited by 62
Winnier, D. A., Fourcaudot, M. J., Norton, L., Abdul‐Ghani, M. A., Hu, S. L., Farook, V. S., Coletta, D. K., Kumar, S., Puppala, S., Chittoor, G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0119941 · Cited by 61
Self-citationShannon, C. E., Ragavan, M., Palavicini, J. P., Fourcaudot, M. J., Bakewell, T. M., Valdez, I., Ayala, I., Jin, E. S., Madesh, M., Han, X., et al. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101154 · Cited by 64
Adipophilin distribution and colocalisation with lipid droplets in skeletal muscle
Shaw, C. S., Sherlock, M., Stewart, P. M., & Wagenmakers, A. J. M. (2009) · Histochemistry and Cell Biology · doi:10.1007/s00418-009-0558-4 · Cited by 59
Metadata
- Authors
- Bays, H., Mandarino, L., & DeFronzo, R. A.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-02-01
- Volume
- 89
- Issue
- 2
- Pages
- 463-478
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2151025367
- Cited by
- 664
- References
- 328
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 20 · 2023: 13 · 2022: 27 · 2021: 12 · 2020: 14 · 2019: 22 · 2018: 24 · 2017: 20 · 2016: 24 · 2015: 31 · 2014: 42 · 2013: 48 · 2012: 28
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
- Keywords
- type 2 diabetes, free fatty acids, lipotoxicity, ectopic fat, thiazolidinediones, adipokines, insulin secretion, hepatic insulin resistance, muscle insulin resistance, adipocyte lipolysis, fat redistribution, impaired glucose tolerance
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Fatty Acids, Nonesterified, Humans, Obesity, Transcription Factors, Adipocytes, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
